Royalty Pharma plc (NASDAQ:RPRX) Position Raised by Deutsche Bank AG

Deutsche Bank AG lifted its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 36.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 3,189,964 shares of the biopharmaceutical company's stock after acquiring an additional 847,704 shares during the period. Deutsche Bank AG owned 0.54% of Royalty Pharma worth $81,376,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Adage Capital Partners GP L.L.C. boosted its stake in Royalty Pharma by 42.6% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 16,968,321 shares of the biopharmaceutical company's stock valued at $432,862,000 after purchasing an additional 5,069,127 shares during the period. Swedbank AB raised its holdings in shares of Royalty Pharma by 10.3% during the fourth quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company's stock valued at $310,308,000 after buying an additional 1,136,800 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Royalty Pharma by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 7,312,551 shares of the biopharmaceutical company's stock valued at $186,846,000 after buying an additional 46,765 shares during the last quarter. Norges Bank acquired a new position in shares of Royalty Pharma during the fourth quarter worth approximately $124,498,000. Finally, Northern Trust Corp boosted its position in shares of Royalty Pharma by 12.8% during the fourth quarter. Northern Trust Corp now owns 3,330,429 shares of the biopharmaceutical company's stock worth $84,959,000 after buying an additional 376,619 shares during the period. Institutional investors own 54.35% of the company's stock.

Royalty Pharma Price Performance

NASDAQ RPRX opened at $33.15 on Monday. Royalty Pharma plc has a 12 month low of $24.05 and a 12 month high of $34.20. The firm has a market capitalization of $19.11 billion, a PE ratio of 22.86, a P/E/G ratio of 2.31 and a beta of 0.49. The company's 50 day simple moving average is $32.39 and its 200 day simple moving average is $29.80. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.99 by $0.07. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. The firm had revenue of $839.00 million during the quarter, compared to analyst estimates of $724.69 million. As a group, equities research analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a dividend of $0.22 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 annualized dividend and a yield of 2.65%. Royalty Pharma's dividend payout ratio is currently 60.69%.

Wall Street Analyst Weigh In

Separately, Citigroup restated a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Royalty Pharma presently has an average rating of "Buy" and an average target price of $42.50.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma plc (NASDAQ:RPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.